We’ve rebranded some of our products, learn more ›

CODEX® is now PhenoCycler,
Phenoptics™ is now Phenolmager.

Fireside Chat: Post-AACR Spatial Biology Trends & Decoding Cancer Insights

Webinar | Wednesday, May 22, 2024

Join the discussion on the latest advancements, new norms, emerging trends and breakthrough topics from AACR by our expert panelists, offering clarity on the current landscape, with a deep dive into the latest advancements on how spatial biology is shaping precision medicine and cancer research. From advancements in immunotherapy to a new norm of precision medicine, navigating through the forefront of cancer research, influencing the trajectory of future treatments and patient care.

Learning Objectives:

  • The complexities of cancer across diverse populations and demographics.
  • Integration of AI and its role in unraveling insights from medical and non-medical datasets, enabling earlier detection and understanding of various disease states.
  • Keeping you informed about the latest developments in oncology, unravel insights from both medical and non-medical datasets, enabling earlier detection and understanding of various disease states




Arutha Kulasinghe

Arutha Kulasinghe, PhD

Scientific Director of the Queensland Spatial Biology Center in Brisbane, Group Leader at The University of Queensland

Dr Arutha Kulasinghe completed his Bachelor of Science and Honours majoring in Medical Microbiology at the University of Pretoria (South Africa). In 2014, he undertook his PhD studies in the investigation of circulating tumour cells in head and neck cancers at the Queensland University of Technology (QUT), receiving his doctorate in 2017. In 2019, Dr Kulasinghe began a Peter Doherty NHMRC Early Career Fellowship to develop biomarkers of immunotherapy response in head and neck squamous cell carcinoma (HNSCC) and lung cancer. His research aims to use spatial analysis of the tumour microenvironment and profiling of liquid biopsy (circulating tumour cells/circulating tumour DNA) to identify biomarkers of response to immune checkpoint inhibitors. Dr Kulasinghe is supported by a number of funding agencies including the NHMRC, Cure Cancer, the PA Research Foundation and the GPRWMF.

Suzanne Coberly

Suzanne K. Coberly, MS, MD, FCAP

Scientific Senior Director, Discovery & Translational Pathology, Oncogenesis TRC, Bristol Myers Squibb

Suzanne K. Coberly, MD, MS is a board certified human anatomic & molecular pathologist with over 20 years of experience in the biotech, IVD, and companion diagnostics industry. She has founded &/or directed multiple translational pathology labs focused on supporting large molecule & antibody therapeutic & CDX prototype development at Amgen, AbbVie & multiple smaller companies. She has also founded and directed clinical development for CDX & IVD tissue based & genomic assays at Agilent Biosciences (DAKO & Agilent genomics). She is now offering CDX/IVD strategic consulting & pathology services at Chimeric Enterprises Pathology Consulting, a virtual biotech pathology practice.

Doug Flora

Dr. Doug Flora

Executive Medical Director of Oncology Services St. Elizabeth
Pascal Bamford

Pascal Bamford, PhD

Senior Vice President, R&D and Laboratory Operations, Akoya Biosciences

Dr. Bamford has a PhD in cell image analysis from the University of Queensland, Australia, and a master’s degree in engineering from the University of Bristol, UK, and Ecole Nationale Supérieure des Télécommunications, France. Dr. Bamford brings multidisciplinary expertise and a dedicated career to developing oncology clinical diagnostic tests from screening to therapy selection at companies such as Roche, Genomic Health and Exact Sciences. He led multiplexing at Ventana Medical Systems and has been a leader in Spatial Biology for over 15 years.